• Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation
• IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s
• IGC-506 is a combination therapy developed from cannabis extracts and other compounds that’s designed to treat multiple types of eating disorders in humans and animals

India Globalization Capital, Inc. (NYSE American: IGC) (FRA: IGS1) anticipates a Patent Cooperation Treaty (“PCT”) filing application by February 28, 2018, for IGC-506, which is designed for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company anticipates a U.S. and national filing by August 28, 2019, the company announced (http://dtn.fm/MsLB4). A PCT filing is an international patent filing effective in a number of foreign countries (http://dtn.fm/UrSh0).

The company has a number of provisional patent filings, either already made or anticipated in the future, which could raise its valuation. It already has three products, scheduled for pre-clinical trials, featuring provisional filings for patents. These include IGC-501, a cream/patch for the treatment of neuropathic pain; IGC-502, a veterinary market product for the treatment of seizures; and IGC-504 for the treatment of eating disorders in adult humans as well as for the veterinary market. In 2018, IGC anticipates a pre-clinical trial for IGC-ADI, which is designed to treat Alzheimer’s disease.

IGC is a Maryland-based company engaged in the development of cannabis-based combination therapies to treat Alzheimer’s, several endpoints of Parkinson’s, pain, nausea, eating disorders and epilepsy in dogs and cats. It has two lines of businesses. The first, legacy infrastructure, consists of heavy equipment rental, commodities trading and real estate management. The other is canna-pharmaceutical.

IGC-506 is a combination therapy drug, developed from cannabis-extracts and other compounds, designed to treat multiple types of eating disorders. Cannabinoids are chemical compounds that exert a range of effects on the body. The non-psychoactive phytocannabinoid, cannabidiol (CBD), influences many pathways in humans, as well as cats and dogs, and may be used to provide relief for numerous symptoms ranging from pain to eating disorders.

For more information, visit the company’s website at www.IGCInc.us

• Multifaceted international company, first and only to offer hemp-infused skin care products in China
• Now set to spin off new subsidiaries
• Shareholders likely to benefit from value-add transaction

In business for nearly two decades, ChineseInvestors.com (OTCQB: CIIX) began as a specialized investment services company providing real-time commentary, analysis and education-related services in the Chinese language. While building recurring revenues through its unique 100,000+ user base, CIIX maintained a long term vision for value-add opportunities. In 2016, the company identified one of the fastest growing markets in the world and entered the explosive new medical CBD market. Targeting the nearly two billion Chinese-speaking people worldwide, ChineseInvestors.com launched into online sales of CBD products and continued to expand its core investor education business, adding a daily video telecast on cryptocurrencies aimed at Chinese speakers.

Initially, forays into the Chinese CBD market focused on global online sales of oils through subsidiary ChineseCBDoil.com. As CIIX gained traction and established a significant footprint in the global CBD market, it then opened a huge untapped market by becoming the first and only known company to offer hemp-infused skin care products in China. The company retails its hemp oil-based cannabidiol (CBD) products on Alibaba and Amazon under the “OptHemp” brand through its wholly-owned subsidiaries, CBD Biotechnology Co. Ltd. and ChineseHempOil.com, Inc.

CIIX’s CBD endeavors have proved so successful that the company just announced plans to spin off its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc. in order to transition the subsidiary from a private startup to a successful public company (http://dtn.fm/m4SEE). Spinning off these entities will allow CIIX to focus on its cryptocurrency division and core financial education business.

ChineseInvestor.com CEO Warren Wang, in a news release, said “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the company’s existing shareholders. The details about the value to the company’s existing shareholders will be announced in the coming weeks.”

CIIX has managed to incubate a high growth company and has intentions of listing the shares of the subsidiary’s common stock for trading on the OTCQB. This initiative should bode exceptionally well for existing shareholders as the realized value of the transaction becomes more apparent. CIIX will now return focus to its core financial education business and its new cryptocurrency division. With its track record of identifying and seizing upon growth opportunities, it wouldn’t be surprising to see CIIX repeat another successful spinoff.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Recreational and medical marijuana market in U.S. estimated to reach $37 billion by 2024
• Need for payment processing solutions increases as cannabis continues march toward legalization
• Cryptocurrency presents a payment option, along with comprehensive card processing solutions

Medical Cannabis Payment Solutions (OTC: REFG), the industry’s leading end-to-end payment processing solution for the legal marijuana industry, gives cannabis retailers and consumers different payment options besides bringing hard cash to the table.

The company’s unique StateSourced proprietary system offers one of the first and only comprehensive card processing operations to serve state-sanctioned marijuana industries. StateSourced is not a prepaid or gift card, which is an important distinction to merchants and clients alike since financial institutions continue to avoid the legal marijuana sector. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant’s use in one form or another.

Medical Cannabis Payment Solutions emphasizes that its debit card can only be used to purchase cannabis-related products from state-sanctioned vendors, which means it must be used for payment within a state where marijuana is legal. The company’s card includes a state-of-the-art system that tracks sales and tax collection, giving businesses a distinct advantage when it comes to client management and meeting regulatory requirements (http://dtn.fm/nfE84).

In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. State-licensed marijuana dispensaries around the country will have the option of accepting StateSourced cards and approved cryptocurrencies, such as Bitcoin and Weedcoin, which frees consumers up from carrying cash to make purchases (http://dtn.fm/XkOC5).

Medical Cannabis Payment Solutions CEO Jeremy Roberts said in a recent interview with NetworkNewsAudio, a service of NetworkNewsWire, that the company’s new website (www.REFG.co) allows consumers to apply online for a StateSourced card.

“We’ll do a short due diligence period as required by law, and then we’ll be able to set up processing for them,” Roberts said in the interview, adding that, once the account is set up, using it is easy, accessible and solves the headache of purchasing product from legal businesses that, until now, have been forced to operate on a cash-only basis.

Numerous industry reports state that the recreational and medical marijuana industries will continue their upward trajectory as the highly-regulated plant becomes more accessible through legalization. A report by Statista shows that the estimated retail sales of medical marijuana in the United States will reach nearly $7 billion by 2021 (http://dtn.fm/8aTvw), but that figure pales somewhat next to the combined market that includes recreational marijuana. The consumer market for both sectors of the marijuana industry is expected to eclipse $26 billion by 2021 (http://dtn.fm/Actt1), with significant increases expected over the following three years, when the market size is expected to reach $37 billion.

Medical Cannabis Payment Solutions provides hand-crafted, secure financial solutions for the cannabis industry. The company’s commitment to providing customers, dispensaries and related businesses working in the state-legalized cannabis markets with real, working solutions to a frustrating problem is front and center on its new website.

For more information, visit the company’s website at www.REFG.co

Let us hear your thoughts: Medical Cannabis Payment Solutions Message Board

• CIIX board has agreed, by the end of February 2018, to spin off its consumer products division in the U.S. and China, including its hemp oil assets and its new wholesale alcohol distribution division
• CIIX plans to register ChineseHempOil.com, Inc. as a separate publicly-traded company to be listed on the OTCQB
• Warren Wang, CEO of CIIX, said that the move will allow these businesses to grow in their respective markets

ChineseInvestors.com, Inc. (OTCQB: CIIX) is spinning off its wholly-owned foreign entity, CBD Biotechnology Co., Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc., to allow itself to focus on its new cryptocurrency division and its core financial education division, the company announced (http://dtn.fm/lN10M).

In a news release, Warren Wang, CEO of CIIX, said, “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc., as we believe the existing business lines and the new acquisitions in China, secured by CEO (of CBD Biotechnology Co., Ltd.) Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the company’s existing shareholders. The details about the value to the company’s existing shareholders will be announced in the coming weeks.”

CIIX is a diverse educational and consulting company for the Chinese-speaking community in China and the U.S. Subscriptions and investor relations have provided the company with key revenue streams. In addition to educational coverage of bitcoin and other cryptocurrencies, CIIX has a core financial education and consulting business.

It has committed itself to cryptocurrency education and active involvement. It broadcasts a daily video from the NYSE titled ‘Bitcoin MultiMillionaire’. It has also recently reached agreement to host a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The unit it hosts has been installed by Blockchain BTM LLC. The start of futures trading in bitcoin on the Chicago Mercantile Exchange by CBOE Global Markets, Inc., according to a MarketWatch report (http://dtn.fm/r99pL), may attract even more investors and simplify the process of gaining exposure to bitcoin for both retail and institutional investors. CNN reported that the new futures trading has spurred even more interest from the investor community (http://dtn.fm/Dcs7N).

Yun added, “The decision to expand CBD Biotechnology’s Chinese Consumer Division to include baijiu liquor sales is part of a strategic plan to increase revenues in the coming year. By aligning with China GuiZhou HanTai Wine, Inc., CBD Biotechnology has partnered with a proven leader in the Chinese baijiu market.” Baijiu is a Chinese alcoholic beverage made from grain.

“In addition to distribution rights, the agreement between CBD Biotechnology and China GuiZhou HanTai Wine, Inc., affords CBD Biotechnology the opportunity to launch its own brand of baijiu in the future,” Yun added. CBD Biotechnology has a huge opportunity to gain significant market share as ultra-premium baijiu is expected to jump 16% in volume per year over the next five years as the number of high-wage earners in China soars.

As part of the transaction, CBD Biotechnology Co., Ltd. will acquire a Chinese Wholesale Alcohol License, expanding its Chinese consumer division to include the distribution of baijiu. On November 7, 2017, the Shanghai Wine Monopoly Bureau issued the license for a three-year term to CBD Biotechnology.

CBD Biotechnology has also entered an agreement with China GuiZhou HanTai Wine, Inc., to distribute its brand of baijiu, Yantai 1985, and partnered with Jinri Toutiao (translation: Today’s Headlines), a popular Chinese mobile app. Jinri Toutiao is the first broad news aggregator in China, featuring real time news, games, movies and music. It has more than 600 million registered users. It will be used for sales and marketing by CBD Biotechnology.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years
• Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids
• Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect

Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017 Marijuana Business Conference & Expo (MJBizCon) in Las Vegas, Lexaria’s chairman and CEO Chris Bunka offered some thoughts on the future of cannabis during an interview with The Street at the LD Micro conference in Los Angeles last week.

“The market potential of cannabis is really exploding worldwide, it’s not just an American phenomenon, it’s happening in Canada, Mexico, Germany, Australia, all over the world,” Bunka told The Street’s Kinsey Grant (http://dtn.fm/8WNgf). “It’s expected to be in the $30-$50 billion range in the next three to four years … and growing very, very rapidly.”

Lexaria BioScience’ss groundbreaking technology is specifically created for the delivery of APIs, or active pharmaceutical ingredients, found in cannabis, vitamins, non-steroidal anti-inflammatory drugs and, even, nicotine.

“We effectively help CBDs get into the bloodstream more rapidly and more efficiently than they otherwise can,” Bunka told Grant in the interview. “We’ve developed this technology – we’re really a research and development company – and we license it off to other companies that have expertise in developing consumer products or cannabis-related products, and they utilize our technology to make those products better.”

The company’s DehydraTECH™ proprietary technology is not only cost effective, it has been proven to enhance the performance of beneficial compounds in ingestible products (http://dtn.fm/tWdB2). An edible cannabinoid product, for instance, becomes better tasting, better smelling, has better bioavailability and absorption, and lasts longer when Lexaria’s patented delivery technology is utilized. Because Lexaria’s technology enables or works with all ingested forms of cannabinoids, the company is seen as an attractive partner with various biotech companies conducting cannabinoid research and development, and it could be an equally attractive acquisition target (http://dtn.fm/Ur8Ya).

Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria additional future growth potential.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Company plans to start processing cannabis payments from subsidiary SingleSeed Payments by January 2018
• Goal is to build a fully integrated solution for cannabis businesses to help manage day-to-day operations from beginning to end
• SING plans more acquisitions in 2018, investing a significant amount of equity and cash into additional companies

SinglePoint, Inc. (OTC: SING) has been cited by the The Greensheet Online Edition for building a “soup-to-nuts” platform for payment processing in the cryptocurrency and cannabis industries (http://dtn.fm/5bZVE). The goal, according to Wil Ralston, SING president, is to have a “fully integrated solution for businesses to manage their day-to-day operations from beginning to end.” Greensheet prominently mentioned SinglePoint in a section titled, “Workarounds Emerging.” It detailed how SinglePoint is a company offering solutions to the cryptocurrency and cannabis industries.

“We already have all the pieces in place to get a credit-debit card solution up and running,” Ralston said. He added that SING is experimenting with a mobile solution for payment processing from subsidiary SingleSeed Payments. It focuses on cannabis dispensaries that have a proprietary bitcoin exchange. “We hope to start processing by mid-January,” he said.

SING also announced that, in 2018, it will continue its growth strategy of pursuing more joint ventures and the closing of new deals within existing agreements. The goal is to solve key issues in the cannabis industry (http://dtn.fm/JD2go).

SING has been acquiring technologies and companies that will eventually support a comprehensive platform for the cannabis industry, with the goal of providing a single platform to manage all operations for companies in the cannabis industry.

SinglePoint is a mobile, high-technology company offering payment processing solutions in high-risk markets, such as the legal cannabis industry. SING is a publicly-traded holding company building its portfolio of undervalued subsidiaries. The cannabis market operates independently of conventional banking. It uses its own proprietary technology to process transactions in bitcoin for the “unbankable” cannabis industry.

The company has already made a number of acquisitions, such as SingleSeed, Convectium and Discount Industry Garden Supply (DIGS). It also strengthened its position in the cannabis and cryptocurrency markets through its recent joint venture agreement with AppSwarm (OTC: SWRM). The agreement calls on the two companies to start development of a proprietary delivery application that will enable licensed delivery services and licensed dispensaries to safely make in-home deliveries.

After achieving a $100 million market cap in December 2017, SING plans continued growth through acquisitions in 2018. Its management remains bullish on bitcoin and blockchain technologies that solve key issues in the cannabis markets. SING will look for additional companies to acquire and partner with in order to bring solutions to this market.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Millions of people in North America report major depression concerns
• Sage Therapeutics drug trials return dramatic data
• Testing phase targets central nervous system biomolecule receptors

Biopharmaceutical company Sage Therapeutics, Inc. (NASDAQ: SAGE) is reporting optimism over recent product testing in its efforts to reduce the debilitating effects of central nervous system disorders such as depression in its varied forms. Company CEO Jeff Jonas told a CNBC interviewer this month that he’s hopeful a pill now known as SAGE-217 may even become as prominently recognized as Prozac in the treatment of major depressive disorder (MDD), or clinical depression (http://dtn.fm/p80OC).

“What we saw in this study was a reduction to such a degree that two-thirds of the patients nearly achieved remission, which is elimination of depressive systems, by two weeks… I’ve been doing this for 20 years, and I don’t think I’ve ever seen data this dramatic in a mid-stage trial,” Jonas said during the ‘Power Lunch’ interview.

MDD reportedly affects millions of people in North America, the principle geographical region where it is recognized and treated globally. In 2015, nearly seven percent of U.S. adults reported episodes of MDD that affected aspects of their lives including appetite, sleep, interest in once-enjoyable activities, ability to reason and act, and, in some cases, their will to live, according to Healthline Media (http://dtn.fm/2rbKm).

“There are currently significant gaps in the disease management of depression and our development goal at Sage is to change patients’ expectations by transforming the treatment landscape for MDD,” Dr. Steve Kanes, chief medical officer for Sage Therapeutics, stated in a December news release (http://dtn.fm/7oCR9).

In November, Sage Therapeutics reported its lead experimental product for intravenously treating postpartum depression — brexanolone, or SAGE-547 — helped women with moderate to severe afflictions by statistically significant margins over placebo in third-stage testing (http://dtn.fm/bD69X). SAGE-217 has just completed smaller scale second-stage testing, but Jonas said the company is confident that the positive results will continue through the next phase of trials as it works with the FDA on potential market approval.

SAGE-217 would offer a side effect and efficacy profile distinct from any other product, as the company works on “brand new science” to calm down the brain, according to Jonas.

“The one challenge is that people are going to have to clear their minds of the old style of thinking about what … anti-depressants do and what they need to do. So we’re going to have to be very innovative in designing our Phase 3 program. We obviously will need one, and that’s the work we’re undertaking right now,” he said.

The company’s products target gamma-Aminobutyric acid (GABA) system receptors in the central nervous system, which are responsible for reducing neuronal excitability and N-methyl-D-aspartate (NMDA) system receptors in nerve cells. The double-blind SAGE-217 test involved 89 eligible patients who reported no serious or severe adverse side effects during the trials involving the neuroactive steroid’s effects on the GABA system. In addition to MDD, the trials analyze the drug’s response to postpartum depression and to the movement disorders essential tremor and Parkinson’s disease.

The company’s portfolio includes anticipated product trials for SAGE-718, which will target “cerebrosterol deficit disorders, Anti-NMDA Receptor Encephalitis and other indications involving NMDA receptor hypofunction” in the hope of eventually developing ways of treating conditions such as depression, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington’s disease, and neuropathic pain.

For more information, visit the company’s website at www.SageRx.com

• Developing blockchain platform for oil and gas industry
• Distributed ledger technology to reduce transaction costs
• Now a member of Enterprise Ethereum Alliance

Blockchain deployment is still new, with a world of opportunities for application. Cloud providers are already moving to offer it as an enterprise service (http://dtn.fm/lM2l6). Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is out to disrupt the oil and gas industry with its new blockchain platform for supply chain management. The platform, to be developed in conjunction with First Bitcoin Capital Corp. (OTC: BITCF), holds the promise of drastically reducing operating costs for the industry. At present, oil is traded through a diverse network of producers, suppliers, contractors, subcontractors, refiners and retailers in such large volumes that tracking the movement of crude is a Sisyphean task. However, the new platform, by employing blockchain technology, will be able to represent physical supplies of crude by digital assets, which remain digitally attached throughout the supply chain journey.

In November 2017, Petroteq Energy announced a co-development agreement with First Bitcoin Capital Corp., under which the companies will develop the new supply chain management platform based on advanced blockchain technology. The new platform, called PetroBloq (www.PetroBloq.com), offers the promise of improving efficiency, transparency and security in the oil and gas industry. According to the company, “PetroBloq will be the first blockchain based platform developed exclusively for the supply chain needs of the oil and gas sector. PetroBloq users will enjoy cost and time savings, increased transparency and the ability to mitigate the constantly evolving geopolitical atmosphere and market fluctuations.”

Presently, the industry relies on an extensive global supply chain that includes domestic and international transportation, ordering, inventory management and control, materials handling, import and export facilitation, refining and information technology. Due to the size and complexity of this system, accurate information is difficult to compile and is usually outdated by the time it is verified and published. However, with blockchain technology transactions for product trades and transfers can be instantly verified across an entire global network without reliance on a central reconciling authority, potentially reducing operating costs, more securely storing and managing data and speeding up the processing of transactions.

A study by Deloitte proffers one example of how the oil and gas industry might benefit from employing blockchain (http://dtn.fm/Kl9x6). By issuing digital tokens with names, perhaps, like Brent or WTI (for West Texas Intermediate), a blockchain-distributed ledger could be used to trade barrels of oil. These tokens would represent the underlying asset (a barrel of oil) and would remain digitally attached throughout the supply chain journey. By using tokens in a blockchain, payment could be processed more quickly, paperwork such as title transfers would be eliminated and disputed transactions would be significantly reduced. Currently, around nine percent of crude oil transactions are disputed, which equates to around $150 billion annually.

Petroteq is moving ahead quickly with its blockchain initiative. On December 4, 2017, it announced that it had joined the Enterprise Ethereum Alliance (EEA), the world’s largest open-source blockchain network (http://dtn.fm/ylZn1). The EEA brings together over 500 enterprises and experts to discuss and develop the ethereum framework, which is currently the only blockchain running in real-world production that supports smart contracts. A smart contract is a program, which encodes the terms of an agreement and is stored, replicated and supervised by a network of computers running a blockchain.

Petroteq has also announced that it is now a member of the API, or American Petroleum Institute (http://dtn.fm/lNIq1). The API is the only national trade association representing all facets of the oil and natural gas industry. It promotes safety across the industry globally and attempts to influence public policy in support of a strong, viable oil and natural gas industry.

Petroteq Energy is also involved in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company has already revolutionized extraction methodology with its introduction of a unique, environmentally safe, continuous flow, closed loop technology – a first in North America and probably in the world – that requires no tailings ponds. With its new blockchain initiative, it is promising to bring that same innovative approach to oil and gas supply chain management.

For more information, visit the company’s website at www.PetroteqEnergy.com

Let us hear your thoughts: Petroteq Energy Inc. Message Board

• Role playing games (RPG) in casino- and movie-themed applications are one of four revenue streams for diverse SWRM, which leverages its large studio relationships
• Management of SWRM hopes to achieve revenues of roughly $7 million by FY2018; company recently entered cannabis mobile app market in joint venture focused on blockchain technology and bitcoin payment options
• Market for virtual reality games is projected to grow to $40 billion by 2020, reflecting a compound annual growth rate (CAGR) of 61.3 percent over five years

AppSwarm, Inc. (OTC: SWRM) markets unique and niche offerings in the role playing games (RPG) market, giving players specialized titles such as ‘Avenging Soldiers’ on Google Play; ‘Komandir – War Front VR’, a virtual reality shooting game; ‘Soccers’, available on the App Store; ‘Dead Uncleansed’ and ‘Turtles, Huh?’.

This market is just one of the revenue streams for AppSwarm, which boasts a growing portfolio of mobile game titles. ‘Avenging Soldiers’ generates sales from in-app purchases that gamers buy to accelerate game play. It boasts four different characters and five unique weapons.

‘Komandir – War Front VR’ puts SWRM in the virtual reality gaming market and is available on Google Play and the App Store. A virtual reality shooting game, it allows players to enjoy a 360-degree immersive gaming environment. It works with numerous VR headsets and offers a number of exciting features, including auto shoot, auto zoom-in and zoom-out and auto aim. This sophisticated game offers users a full battle scene.

SWRM is a high-technology application acceleration firm which engages in joint ventures as well as marketing and developing in the multi-platform games industry. Interactive development and joint ventures play an important role in the company’s growth strategy. Management of the company projects revenues of $6 million to $7 million by FY2018, according to Ron Brewer, CEO and director of AppSwarm (http://dtn.fm/Hng3G).

The company’s management team recently used its business and technical expertise to enter the cannabis mobile app market through its partnership with SinglePoint, Inc. (OTC: SING). The two firms have agreed to conduct a shared rollout of mobile applications (http://dtn.fm/U5Imv). These are specifically focused on solving issues is the cannabis space using blockchain technology and bitcoin payment options. The apps will be available where legal and feasible, but not in all 50 states.

According to SuperData Research, as quoted by Virtual Reality Reporter, the virtual reality video games market is expected to reach $40 billion by 2020, with a nine-fold jump in households that have at least one VR device (http://dtn.fm/Eai55). The dollar growth shown by SuperData Research reflects a five-year compound annual growth rate (CAGR) of 61.3 percent. The report finds that platforms driving the growth will be PC ($16.3 billion), mobile ($15.6 billion) and console ($8.5 billion). Software sales in virtual reality are projected to reach $24.5 billion by 2020, with $15.9 billion in hardware sales.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Demand for lithium expected to increase by over 300 percent by 2025
• Standard Lithium has a strong technical team to process established reserves
• The company is exploring other potentially highly lucrative reserves

On the back of the growing global demand for cleaner energy, lithium producers are leading the way by providing the essential element for batteries in electric cars. Fortune magazine reports that the production of electric cars will increase by almost three percent by 2020 and 10 percent by 2025 (http://dtn.fm/fD813). The demand for lithium is set to increase by more than 300 percent over the next eight years, prompting lithium mining companies to step up their efforts for a leading position on the market. Already a prominent lithium developer, Vancouver-based energy exploration and development company Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is expanding its operations and recently announced an expansion of its lithium brine project in California.

The company announced on December 11, 2017, that it has installed six new separate evaporation ponds at its Bristol Dry Lake property in the Mojave Desert of California. Standard Lithium is taking advantage of the region’s record-high evaporation rates to pre-concentrate brines produced from the project, from where it will be shipped to the company’s testing and processing facilities located at three campuses across North America. In addition, Standard Lithium is undertaking drilling work with four exploration boreholes completed and two more planned. Preliminary results equal and exceed historic data, with the full QA and QC results to be released in the first half of 2018.

The Bristol Dry Lake project covers an area of over 33,000 acres including both patented and placer mineral claims and private property. Recently acquired geophysical data indicates that the basin is deep and expansive. Historical drill samples have shown lithium contents of over 100mg/l over the drilled interval. Bristol Dry Lake is an established mining area with world class infrastructure at the project, paved road and rail access, water and electricity. Standard Lithium has inked agreements with two of the established brine producers in the region, National Chloride Corporation of America and TETRA Technologies (NYSE: TTI), to explore and develop the area for potential lithium production. Under the agreements, the company can conduct exploration, brine sampling, extraction, evaporation and process testing.

Standard Lithium has brought together a strong team of scientists and process engineers to advance the project by applying a hybrid approach, utilizing both conventional and modern extraction processes. With a focus on producing high-quality lithium at low cost to meet global demand, Standard Lithium’s mission is to develop lithium resources that can be brought into production quickly while minimizing project and process risks.

Standard Lithium has also entered into an agreement to explore the highly promising brines over an area of approximately 30,000 acres in the Smackover Formation, which transverses Texas, Arkansas and Louisiana. This offers a low-risk investment with good potential returns in a region with well understood geology. It also has a long history of brine production and the infrastructure for profitable mineral extraction. Historical analysis of the Arkansas Smackover Fromation showed a lithium content of 365mg/l.

Lithium is set to become a highly valuable commodity as the world turns to vehicles driven by electric batteries instead of fossil fuels and, also, with the exponential increase in the use of mobile devices. As the global demand for lithium takes off, producers around the world are expected to have a hard time keeping up, resulting in a market deficit. Standard Lithium has secured reserves to process and will continue to develop other opportunities to meet worldwide demand.

For more information, visit the company’s website at www.StandardLithium.com